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pathogenesis, such as serum amyloid A, a biomarker of sar-
coidosis activity, involved in innate immune response, in-
flammation and apolipoprotein metabolism. In this review 
lipid metabolism alteration and atherosclerosis risk in sar-
coidosis patients were discussed in order to contribute to 
this novel and interesting research topic. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 Sarcoidosis is a systemic granulomatous disease of un-
known origin characterized by accumulation of activated 
proliferating T lymphocytes and mononuclear phago-
cytes in affected organs  [1, 2] . Interaction between anti-
gens and antigen-presenting cells polarizes T lympho-
cytes to the T helper 1 phenotype, followed by lympho-
cyte, macrophage, epithelioid and giant cell recruitment, 
proliferation, activation, and differentiation, determin-
ing formation of granulomas  [1–3] .
 The clinical expression, natural history and progno-
sis of sarcoidosis are unpredictable, and no reliable indi-
cators of clinical outcome are available. Some patients
experience spontaneous remission and others develop 
chronic persistent disease, sometimes with relapses and 
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 Abstract 
 Sarcoidosis is a systemic granulomatous disease of unknown 
etiology. Recent studies demonstrated that its pathogenesis 
is related with enhanced oxidative stress (protein carbonyl-
ation and lipid peroxidation) and alterations in the circulat-
ing lipid profile. Alterations of lipid metabolism (including 
the reduction in high-density lipoprotein cholesterol levels 
and apolipoprotein A1 concentrations) induce plasma mem-
brane, bronchial and lung capillary endothelial cell damage 
in sarcoidosis patients. Dyslipidemia is associated with in-
creased oxidative stress, diminished overall antioxidative 
protection and increased risk for atherosclerosis. Very re-
cently increased cardiovascular biomarkers (in particular al-
terations of lipoprotein A and d-dimer concentrations) were 
observed in sarcoidosis patients, mainly in those with a high 
risk of atherosclerosis. Chitotriosidase, a biomarker of sar-
coidosis activity and macrophage activation, is increased in 
serum and bronchoalveolar lavage fluid of patients with sar-
coidosis as well as in patients with atherosclerosis. Lipi-
domics and other recent methodologies allowed the discov-
ery of proteins involved in lipid metabolism and sarcoidosis 
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different responses to treatment  [1, 2] . Acute sarcoidosis 
is associated with Lofgren syndrome while chronic sar-
coidosis has insidious onset and slow progression with 
large variations between individuals and almost invari-
able lung involvement. Symptoms, if any, are usually few 
(dry cough, dyspnea, chest pain, and rarely a low fever). 
In progressive advanced forms with fibrotic lung involve-
ment there may be severe hypoxemia and pulmonary hy-
pertension  [1–4] .
 The pathogenesis of sarcoidosis has been associated 
with activation of alveolar macrophages and T lympho-
cytes that release a broad spectrum of mediators, such as 
cytokines, enzymes and chemokines, that modulates 
granulomatous inflammation as well as lipid metabolism 
 [1, 5] . Changes in lipid metabolism have been shown to 
damage the plasma membrane  [5] , as well as bronchial 
and lung capillary endothelial cells. Sarcoidosis has re-
cently been associated with an increased pulse wave in-
dex, which may indicate an early stage of atherosclerosis 
 [6–10] . Enhanced production of reactive oxygen species 
and alterations in circulating lipid profile have been re-
ported in this granulomatous disease  [11, 12] .
 Oxidative stress and altered lipid metabolism are 
thought to play a role in the pathogenesis of sarcoidosis, 
although the significance of blood oxidative stress/anti-
oxidant defense and alterations in lipid status parameters 
in sarcoidosis is unclear  [13] . Interestingly, dyslipidemia 
has been associated with increased oxidative stress and 
diminished overall antioxidative protection but the po-
tential role of changes in lipid metabolism in the patho-
genesis of the disease has not been widely investigated 
 [11–13] . In the last 15 years, certain authors have begun 
to investigate the proteins involved in lipid metabolism in 
sarcoidosis, finding a reduction in high-density lipopro-
tein (HDL) cholesterol levels and apolipoprotein A1 
(apoA1) concentrations in patients with active disease. 
This suggested increased risk of atherosclerosis in sar-
coidosis patients, irrespective of exposure to steroids  [14–
18] . Lipidomics showed that several proteins involved in 
lipid metabolism, including serum amyloid A, are ex-
pressed differently in patients than in controls  [19] . This 
protein, involved in innate immune response, inflamma-
tion, and apolipoprotein metabolism, proved to be a bio-
marker of sarcoidosis activity. It displaces apoA1 induc-
ing HDL catabolism in sarcoidosis  [20] .
 In this review we collect the last 10 years of literature 
on lipid metabolism and atherosclerosis risk in sarcoid-
osis patients with the aim to discuss their potential patho-
genetic role in sarcoidosis.
 Lipid Metabolism and Alteration of Capillary 
Endothelial Cells 
 Lipid metabolism alteration plays a role in the early 
phase of sarcoid formation  [4, 5] . It damages the plasma 
membrane and bronchial and lung capillary endothelial 
cells, as recently demonstrated by immunohistochemis-
try  [5] . A role of lipid biology in the development of sar-
coidosis is indicated by observations on endothelial cells 
and membrane proteins present in the surface of the en-
dothelium in lung samples from patients with initial-
stage disease  [5] . Capillary endothelial cells from patients 
showed droplets containing saturated and unsaturated 
fatty acids in the cytoplasm, as well as in the capillary lu-
men, suggesting that endothelial damage may precede 
granuloma formation  [5] .
 Adipophilin has recently been described among the 
membrane proteins contained in these lipid droplets in 
sarcoidosis tissue  [6] . Also known as perilipin 2, this in-
teresting protein binds lipids with high affinity and is in-
volved in liver fibrosis and lung cancer. It has recently 
been analyzed by immunohistochemical staining in sar-
coidosis lung tissue. Altered protein expression with lo-
cal, mainly intracellular, distribution in clustered histio-
cytes has been reported to be a typical feature of sarcoid-
osis  [6] .
 Morphological evaluation of damage to respiratory 
tract capillary endothelial cells in patients with sarcoid-
osis also showed that lipid droplets exhibiting dark mono-
phasic density (unsaturated fatty acids) were surrounded 
by abundant lysosomes in the cells  [7] . In this granuloma-
tous disease, biphasic lipid droplets with dark and lucent 
(saturated fatty acids) densities, accompanied by a few 
lysosomes containing the residual bodies of undigested 
lipid-containing substances, have been reported in respi-
ratory tract biopsies  [7] . The plasma membrane is fre-
quently damaged in capillary endothelial cells containing 
biphasic lipid droplets and lucent monophasic droplets, 
as well as in those with dark monophasic droplets. Lipid 
droplets in respiratory tract capillary endothelial cells 
from sarcoidosis patients have been closely associated 
with mitochondrial alterations, including large number, 
mobilization, and remarkable morphological changes in-
cluding swelling  [7] .
 Considering the lipid modifications observed in endo-
thelium of sarcoid lungs, the risk of atherosclerosis has 
recently been evaluated in these patients by angiogenic 
analysis and peripheral cardiovascular biomarker assay 
 [8] . An altered ankle brachial index with respect to con-
trols was reported irrespective of systemic treatment. In 
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the same population increased cardiovascular biomark-
ers (especially peripheral concentrations of lipoprotein A 
and d-dimer) were demonstrated, and it was concluded 
that this granulomatous interstitial lung disease is char-
acterized by an increased pulse wave index, which indi-
cates early-stage atherosclerosis.
 The increased risk of atherosclerosis in sarcoidosis pa-
tients was confirmed in another very recent publication. 
The study considered the subgroup of cardiac sarcoidosis 
patients and demonstrated that atherosclerosis was facil-
itated by upregulation of cholesterol absorption and 
downregulation of cholesterol synthesis  [9] .
 Oxidative Stress Associated with Dyslipidemia 
 Reactive oxygen species released by phagocytes are in-
volved in the pathogenesis of several diffuse lung diseases, 
including sarcoidosis. The crucial roles of nitrosyl-in-
duced stress and lipid peroxidation in the pathogenesis of 
sarcoidosis have been reported by many authors  [10–17] 
as well as higher concentrations of carbonylated proteins 
in bronchoalveolar lavage (BAL) fluid of sarcoidosis pa-
tients with respect to controls, indicative of the contribu-
tion of oxidatively modified proteins to the development 
of the disease  [15, 16] .
 Among the markers of lipid peroxidation, 8-isopros-
tane has been analyzed in BAL fluid and exhaled breath 
condensate from patients with sarcoidosis  [12] and was 
found to be higher with respect to controls. To validate 
the prognostic value of this marker, its concentrations in 
exhaled breath from patients with sarcoidosis were cor-
related with disease severity parameters. It was concluded 
that low initial 8-isoprostane concentrations may be a 
positive prognostic factor and that lipid peroxidation 
plays a crucial role in lung inflammation in active sar-
coidosis  [12] . More recently, 8-isoprostane levels were 
also measured in serum and BAL fluid from patients with 
sarcoidosis or idiopathic pulmonary fibrosis and con-
trols. They were much higher in the former, sustaining 
the hypothesis that lipid peroxidation plays a major role 
in this granulomatous inflammatory disorder  [14] .
 In 2012, a paper was published on oxidant-antioxidant 
balance and lipid metabolism in sarcoidosis  [13] . Inter-
estingly, increased oxidative stress burst (associated with 
increased malondialdehyde, superoxide anion, total oxi-
dant status, prooxidant-antioxidant balance and triglyc-
eride) and reduced antioxidant defense status (low super-
oxide dismutase activity and HDL cholesterol concentra-
tions) were recorded in patients with sarcoidosis. Serum 
and erythrocyte malondialdehyde were the strongest pre-
dictors of disease, and elevated oxidative stress had high-
er clinical accuracy than lipid status abnormality  [13] . It 
was clearly stated that oxidative stress and lipid status pa-
rameters altered with respect to controls indicated an in-
creased risk of atherosclerosis.
 Lipidomics 
 The “-omics” sciences (genomics, proteomics, metab-
olomics) collectively characterize and quantify a pool of 
biological molecules to obtain insights into the pathoge-
netic mechanisms, clinical phenotyping and prognosis of 
a specific disease. Lipidomics is based on large-scale stud-
ies of the lipid pathways and networks involved in a spe-
cific condition. The first “omic” applied to the study of 
sarcoidosis was proteomics that led to the identification 
of different protein pathways and profiles involved in its 
pathogenesis  [16] . Classical 2-dimensional electrophore-
sis applied to the study of bronchoalveolar lavage showed 
that proteins involved in lipid metabolism were altered in 
sarcoidosis and involved in its development  [18, 19] .
 In a recent proteomic study, various BAL proteins 
(such as plastin 2, fatty acid binding protein, annexin A2 
and apoA1) involved in the regulation of lipid metabo-
lism were found to be expressed differently in sarcoidosis 
patients and controls  [19] . Proteins downregulated in 
sarcoidosis included plastin 2 and fatty acid-binding pro-
tein 4. The latter regulates fatty acid metabolism and cho-
lesterol trafficking and is expressed by adipocytes and 
macrophages. In sarcoidosis patients, increased LDL up-
take and cholesterol efflux seem to be facilitated by a def-
icit in fatty acid binding protein 4 in alveolar macro-
phages  [18, 19] . Another protein involved in lipid me-
tabolism and expressed differently in BAL fluid of 
sarcoidosis patients is apoA1. Its main function is to re-
move low-density lipoprotein (LDL) particles present in 
foamy macrophages, inhibiting expression of proinflam-
matory cytokines  [18, 19] . Anomalous lipid droplets in 
the respiratory tract of sarcoidosis patients may explain 
the protein’s increase in BAL fluid  [18, 19] . Increased se-
rum concentrations of triglycerides are associated with 
high levels of zinc-α 2 glycoprotein, involved in lipid pre-
sentation to CD4 cells  [19] . Insulin resistance in sarcoid-
osis patients is mainly regulated by 2 specific proteins 
identified by a proteomic approach and elevated in BAL 
fluid of sarcoidosis patients: retinoid binding protein 4 
and α 2 -HS-glycoprotein  [19] .
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 Different research groups have also used lipidomics to 
identify serum amyloid A (SAA) in BAL fluid and serum 
of patients with sarcoidosis, demonstrating that this acute 
phase protein is overexpressed and involved in disease 
pathogenesis  [19–21] . Validation of the proteomic results 
by quantitative assays allowed the authors to demonstrate 
that SAA is a prognostic biomarker (being elevated in 
acute sarcoidosis with respect to inactive disease). It is 
also useful for ruling out sarcoidosis because it is only in-
creased in sarcoidosis and not in other granulomatous 
lung diseases, such as tuberculosis  [20, 21] .
 Salazar et al.  [22–24] demonstrated in many studies 
that SAA concentrations are significantly higher in ac-
tive sarcoidosis patients than controls, especially in those 
with severe anomalies of lipid metabolism, such as low 
HDL cholesterol levels and apoA1 concentrations. SAA 
emerged as a key molecule regulating innate immune re-
sponses and inflammation in sarcoidosis through Toll-
like receptor 2  [25] . It proved to be involved in apolipo-
protein metabolism during inflammatory responses by 
displacing apoA1, inducing HDL catabolism or inhibit-
ing lecithin-cholesterol acyltransferase activity  [24] . The 
prognostic role of SAA as a biomarker of sarcoidosis was 
further confirmed by surface-enhanced laser desorption 
ionization time-of-flight mass spectrometry  [25, 26] . An-
other interesting finding was that the increase in SAA 
concentrations in sarcoidosis patients is associated with a 
decrease in paraoxonase 1, an enzyme involved in HDL-
mediated antioxidant and anti-inflammatory functions. 
Paraoxonase 1 dysfunction seems to follow the granulo-
matous inflammation and oxidative stress typical of sar-
coidosis  [27] .
 A list of proteins identified by lipomics and involved 
in lipid metabolism and sarcoidosis pathogenesis has 
been included in  Figure 1 .
 By combining proteomic results with genomic and 
transcriptomic findings, a research group identified some 
candidate genes (SERPINB1, FABP4, S100A8, HBEGF, 
IL7R, LRIG1, PTPN23, DPM2, and NUP214) linked to 
disease susceptibility and immune regulation, apoptosis, 
inhibition of protease activity, and lipid metabolism  [28] .
 Chitotriosidase in Atherosclerosis and Sarcoidosis 
 Sarcoidosis and atherosclerosis are both inflammatory 
diseases in which activated macrophages are crucial be-
cause they release proinflammatory mediators, such as 
chitotriosidase. Atherosclerosis is associated with accu-
mulation of lipids in artery walls after deposition of LDL 
cholesterol and fibrous matrix. In the early stage of this 
disease, monocytes differentiate into foam cells (lipid-
loaded macrophages generated by massive uptake of 
modified LDL) that take part in inflammatory responses 
Zinc-?2 
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amyloid A
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Lipid peroxidation
Lipidomics
LDL metabolism
Lipid presentation
Lipid-binding protein
Perilipin 2
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protein 4
 Fig. 1. Proteins involved in lipid metabo-
lism and atherosclerosis risk in sarcoidosis 
as assessed by lipidomics. 
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and tissue remodeling in the arterial intima (vessel lumen 
narrowing and intimal thickening associated with in-
creased risk of thrombosis)  [29–32] . Lipid accumulation 
promotes gene expression in macrophages, affecting the 
inflammatory process that occurs in atherogenesis  [33] . 
Higher concentrations of chitotriosidase have been re-
ported in the serum of patients with atherosclerosis than 
in controls (55-fold increase) as well as in sarcoidosis pa-
tients  [29–32] . Chitinase 1 plays a role as inflammatory 
and profibrotic molecule in both diseases, suggesting that 
it may be a useful disease biomarker and indicator of ath-
erosclerotic plaque formation, as well as in pulmonary 
granulomatous inflammation  [34–36] . Human chitotrio-
sidase concentrations, related to lipid-laden macrophages 
in human atherosclerotic vessel walls  [29] , generally in-
crease with age and depend on accumulation of lipid-
filled macrophages during progression of atherosclerosis 
 [37, 38] . Macrophage accumulation localized in the su-
pra-aortic and coronary vessels is associated with in-
creased serum CHIT1 activity, which reflects the state of 
activation of macrophages  [29] ( Fig. 2 ). Average CHIT1 
activity in serum remained constant after 6 months of 
cholesterol- and triglyceride-lowering treatment with 
atorvastatin or bezafibrate, suggesting that LDL choles-
terol and triglyceride reduction obtained with both drugs 
did not modify macrophage CHIT1 expression/activity 
in these subjects. Correction of the plasma lipid profile 
does not seem to affect the CHIT1 expression level in 
vivo, supporting the idea that CHIT1 activity cannot be 
used to monitor progression of atherosclerosis  [38–43] .
 In conclusion, lipid metabolism seems to be altered in 
sarcoidosis and to contribute to disease pathogenesis. 
Sarcoidosis and atherosclerosis share several inflamma-
tory mechanisms and biomarkers, such as chitotriosidase 
which is considered a reliable bioindicator of macrophage 
activity in both diseases.
 Lipid alterations are related to oxidative stress and 
granulomatous inflammation. Patients with sarcoidosis 
show alterations in several cardiovascular biomarkers, 
overexpression of proteins involved in HDL and fatty 
acid metabolism, and cholesterol trafficking, increasing 
the risk of developing atherosclerosis.
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 Fig. 2. Human chitinase 1 (chitotriosidase) 
is a marker of activated macrophages in-
volved in pulmonary sarcoidosis and in 
atherosclerosis. 
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